[Treatment of acute intermittent porphyria with a new protein-bound lyophilized hematin].

Abstract

Hematin (iron-III-protoporphyrin 9) has been used for several years in the treatment of acute attacks of inducible porphyrias. Three patients were treated with a new, albumin-bound lyophilized hematin preparation (manufactured by Behringwerke). In all patients it achieved a reduction in the urine of the porphyrin precursors porphobilinogen and 5-aminolevulin acid. In two patients the clinical symptoms were clearly improved, while a third patient died with tetraparesis. Hematin administration proved superior to the preceding glucose treatment. No abnormality of clotting or thrombophlebitis was detectable after hematin infusion.

• Authors: T Fuchs, H Ippen
• Journal: Deutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 112 Issue 34 Pg. 1302-5 (Aug 21 1987) ISSN: 0012-0472 [Print] Germany
• Vernacular Title: Behandlung der akut intermittierenden Porphyrie mit einem neuen, an Albumin gebundenen lyophilisierten Hämatin.
• PMID: 3622268 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Heme
• Hemin
• Porphobilinogen

Topics

• Acute Disease
• Adult
• Female
• Freeze Drying
• Heme (analogs & derivatives)
• Hemin (therapeutic use)
• Humans
• Porphobilinogen (blood)
• Porphyrias (blood, drug therapy)
• Protein Binding